b. Trend in Industrial Design applications 35 c. Country Comparison 36 d. Case Study: Bajaj Auto Ltd. v/s RanomotoGulsar 37 8. Patents 39 a. Section V 40 b. Product Patents 48 c. Product Patents in Pharma 50 d. Trends in Patent applications 54 e. Country Comparison 55 f. Case Study: Apple v/s Samsung 56 9. Conclusion 59 10. Bibliography
Free Trademark Intellectual property
Case Study: ! From humble beginnings to world’s largest biotech September 29‚ 2104 • 1980 Today: • • 1982 1983 ! Amgen is world’s largest biotechnology company • 1984 • 1985 Deal exclusively with biologics • 1987 • 1989 • 1991 20‚000 global employees in North America‚ Europe‚ Asia‚ Australia‚ and Middle East Over $18 billion in annual sales 43% of revenue still
Premium
amortization expense Patent impairment losses All of the above Question 2. 2. (TCO C) Which of the following costs incurred with developing computer software for internal use should be capitalized? (Points : 5) Evaluation of alternatives Coding Training Maintenance Question 3. 3. (TCO C) Mini Corp. acquires a patent from Maxi Co. in exchange for 2‚500 shares of Mini Corp.’s $5 par value common stock and $75‚000 cash. When the patent was initially issued
Premium Stock Income statement Discounted cash flow
if the lawsuit is lost. This analysis includes how the accounting team will need to account for the contingency and how that will change if the client loses the lawsuit‚ affecting the client’s ability to pay the mortgage debt and impairment of the patent. In 1975‚ the Financial Accounting Standards Board published Statement of Financial Accounting Standard No. 5‚ Accounting for Contingencies. SFAS No. 5 defines a contingency as “an existing condition‚ situation‚ or set of circumstances
Premium Bankruptcy Balance sheet Finance
court in California claiming that Ocular ’s Colors contacts lens violated five patents on CIBA color technology. CIBA was looking to have the court prevent Ocular Sciences from selling the lenses. (Roca‚ A 2006) A settlement in October 2002 was reached between CIBA and CooperVision regarding the patent-infringement lawsuit involving the color contact lens issue. (Roca‚ A 2006) CIBA agreed to license the color lens patents to CooperVision for a royalty and some cross-license of some of CooperVision
Premium Eye Visual perception Ophthalmology
lose its patent protection. The problem is that they do not have any suitable replacements for the revenue that will soon be lost due to the emergence of generic drugs following a branded drugs loss of patent protection. Their main source of revenue‚ Lipitor (sales of $10 billion last year)‚ will lose its patent protection in 2010. 4 Alternative/Suggested Solution Above Figure highlights 5 possible marketing strategies solutions that Pfizer can make to face the problem of Lipitor patent expiry
Premium Marketing Competition Brand
Goodwill generated internally. 12. Cost of testing in search for product alternatives. 13. Goodwill acquired in the purchase of a business. 14. Cost of developing a patent. 15. Cost of purchasing a patent from an inventor. 16. Legal costs incurred in securing a patent. 17. Unrecovered costs of a successful legal suit to protect the patent. 18. Cost of conceptual formulation of possible product alternatives. 19. Cost of purchasing a copyright. 20. Research and development costs. 21. Long-term receivables
Premium Balance sheet Generally Accepted Accounting Principles Asset
include; patent‚ copyright‚ industrial design‚ and trademark. A patent is a government grant giving the right to eliminate others from making‚ using or selling an invention. A Canadian patent is protection within Canada for 20 years from the date of filing of the patent application. The patent application is open for public inspection 18 months after filing. Patents can be received for products‚ processes‚ machines‚ manufactures‚ or compositions of matter that are new and useful. The patent owner
Premium Intellectual property Copyright Trademark
SWOT analysis of the Glaxosmithkline. Glaxosmithkline is‚ after Pfizer Inc‚ the largest pharmaceutical company in the world. It was formed in 2000 as the result of a merger between two large companies GlaxoWellcome and SmithKlineBeecham. The company operates primarily in 117 countries‚ their products are currently manufactured in 37 and are sold in over 140 countries. It is headquartered in Brentford‚ England and employs about 110‚000 people with sales of Ł22.7bn. Their strategies for the future
Premium
E9-1 The following expenditures relating to plant assets were made by Spaulding Company during the first 2 months of 2011. 1. Paid $5‚000 of accrued taxes at time plant site was acquired. 2. Paid $200 insurance to cover possible accident loss on new factory machinery while the machinery was in transit. 3. Paid $850 sales taxes on new delivery truck. 4. Paid $17‚500 for parking lots and driveways on new plant site. 5. Paid $250 to have company name and advertising slogan painted on new
Premium Depreciation